Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$39.20
Change (%) Stock is Up 0.85 (2.22%)
Volume247,822
Data as of 11/24/17 1:00 p.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting (Live)
12/11/17 at 8:15 p.m. ET
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting
Monday, December 11, 2017 8:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Presentation
Download Documentation Corporate Presentation (November 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
11/13/17Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
Based on DSMB Review, Patients Age 12 to 17 Can Now be Enrolled in Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study evaluating voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD), has completed its first sch... 
Printer Friendly Version
11/07/17Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopharmac... 
Printer Friendly Version
11/02/17Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the third quarter ended September 30, 2017. “We continue to make important progress toward our goal of bringing GBT440, now known by the non-proprietary name voxelotor, to patients of all ages as a potentially disease-modifying therapeutic option in sickle cell disease,” said Ted W. Love, M.D., president and chief execut... 
Printer Friendly Version
11/01/17Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting
Results from HOPE-Kids 1 Study Expanded Dose Cohort Selected for Inclusion in ASH Press Program Company to Host Investor Webcast on Monday, December 11 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting the clinical development of voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD) will be presented during the 59th American Society of Hematology (ASH) Annu... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
12/11/17 8:15 p.m. ET
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.